Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:27:09 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:SCYX - SCYNEXIS INC - https://www.scynexis.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SCYX - Q0.20.6501·0.7950.40.759+0.06869.9213.21327290.7104  0.78  0.70021.3098  0.56818:09:00Jan 2815 min RT 2¢

Recent Trades - Last 10 of 729
Time ETExPriceChangeVolume
18:09:00Q0.76030.06997
16:00:00Q0.7590.0686200
16:00:00Q0.7590.06861
16:00:00Q0.7590.0686100
16:00:00Q0.7590.0686200
16:00:00Q0.7590.0686100
16:00:00Q0.7590.06861,000
16:00:00Q0.7590.06861,000
16:00:00Q0.7590.06861,100
16:00:00Q0.7590.06861,085

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-28 08:00U:SCYXNews ReleaseSCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
2026-01-21 08:00U:SCYXNews ReleaseSCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
2025-12-22 08:00U:SCYXNews ReleaseSCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
2025-11-19 07:00U:SCYXNews ReleaseSCYNEXIS Completes Transfer of BREXAFEMME(TM) New Drug Application to GSK
2025-11-17 10:15U:SCYXNews ReleaseScynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
2025-11-05 16:20U:SCYXNews ReleaseSCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-10-15 08:00U:SCYXNews ReleaseSCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
2025-09-30 08:00U:SCYXNews ReleaseSCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
2025-09-04 08:30U:SCYXNews ReleaseSCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
2025-08-25 08:00U:SCYXNews ReleaseSCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 - 10, 2025
2025-08-13 16:30U:SCYXNews ReleaseSCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-05-28 08:30U:SCYXNews ReleaseSCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
2025-05-15 16:20U:SCYXNews ReleaseSCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-04-08 08:00U:SCYXNews ReleaseSCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
2025-03-12 17:09U:SCYXNews ReleaseSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update